Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Health
Theme: Public-private partnerships
Destination: Innovative Health Initiative
Action type: Research and Innovation actions
Partnership: IHI (JU-JTI)
Countries involved: Ireland,Netherlands,United Kingdom,Belgium,Spain,Italy,Sweden,Estonia,France,Slovenia,Greece,Switzerland,Hungary,Lithuania,Finland
Call: Clinical validation of biomarkers for diagnosis, monitoring disease progression and treatment response (HORIZON-JU-IHI-2024-07-single-stage, 2024)
Start date: 2025-01-01
End date: 2029-12-31
Duration (months): 60.0
Total project cost (EUR): 22872818.75
EU funding (EUR): 13615935.25
Participants: 30
Project status: SIGNED

BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility. This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care. BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology. By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care. The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects. The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.

Keywords: prostate cancer,bladder cancer,oncology,personalized oncology,sequencing,ngs
Habitability of Exo-Earths in various atmospheric oxidative conditions (OxyPlanets)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Universe Sciences
Panel description: Astro -physics/ -chemistry/ -biology; solar system; planetary systems; stellar, galactic and extragalactic astronomy; cosmology; space sciences; astronomical instrumentation and data
Countries involved: France
Call: ERC ADVANCED GRANTS (ERC-2021-ADG, 2021)
Start date: 2022-10-01
End date: 2027-09-30
Duration (months): 60.0
Total project cost (EUR): 2412601.0
EU funding (EUR): 2412601.0
Participants: 1
Project status: SIGNED

Among the thousands of extrasolar planets discovered, Earth-like objects focus our attention to seek new habitable worlds. Eleven Earth-sized planets have already been discovered in the Habitable Zone (HZ) of their host-star, including three in the TRAPPIST-1 planetary system. Deciphering their atmospheres is the challenge of the next decade in exoplanetary science, stressing out urgent needs in fundamental data for these objects. My aim is to investigate how the atmospheric organic reservoir forms and evolves in the frame of humid exoplanetary atmospheres in Habitable Zone. I will also quantify the impact of theses processes on the climate and on the potential for prebiotic chemistry on these planets. I propose to consider the role of organic aerosols as prebio-signature: those are nanoparticles chemically produced in the atmosphere. I will address the capacity of exo-Earths atmospheres to produce organic aerosols in various oxidative conditions, and their further physical and chemical interactions with atmospheric water. To tackle these questions, I will combine experiments and models to discover the reactivity that occurs in atmospheres within an extensive range of oxidation conditions. I will experimentally determine the physical properties of the aerosols, and then model their radiative impact and their propensity to generate clouds in the atmosphere. I will also experimentally identify the prebiotic molecules composing the aerosols that dissolve into clouds. This transfer from the dry organic reservoir towards liquid water is indeed critical for the emergence of life. The ERC-AdG Oxyplanets project will contribute to interpret and suggest observations for the future NASA-JWST and ESA-ARIEL space missions. Furthermore, it will reinforce our knowledge of the habitability of Earth-like exo-worlds, potentially reappraising the conditions for life to appear on the early-Earth.
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor (SilkPlatelet)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Challenges
Action type: EIC actions
Countries involved: Italy,France,United Kingdom,Germany
Call: Medical Technology and Devices: from Lab to Patient (HORIZON-EIC-2021-TRANSITION-CHALLENGES-01, 2021)
Start date: 2022-10-01
End date: 2025-12-31
Duration (months): 39.0
Total project cost (EUR): 1798152.5
EU funding (EUR): 1798152.5
Participants: 6
Project status: SIGNED

The generation of ex vivo functional megakaryocytes (MK) and platelets is questioning current transfusion medicine exclusive reliance on blood donors to produce platelets. The demand for platelets is, in fact, in continuous rise, driven by an aging population, advances in medical procedures and even more aggressive cancer therapies, although the supply of blood donors continues to remain stagnant. Ex vivo platelet production systems have then emerged as a feasible supply that can moreover secure universal compatibility to avoid platelet refractoriness. If during the FET Open application we have proved that the platelet production ex vivo can be precision-tailored with the correct physical and biochemical environment, now with SilkPlatelet our consortium is looking forward to demonstrating the feasibility of an upscaled ex vivo production system. To bring then our technology from TRL4 to TRL6 we will increase the ex vivo platelet production capacity with media and stem cells aligned to GMP requirements for large-scale clinical transfusion. Our goal is to produce universal platelets particularly for patients with immune reaction to previous transfusions with HLA null platelets and patients with acute hemorrhage. At the core of our ?from lab-to-patients? roadmap, we will find both UNICAM proprietary technology to differentiate stem cells into MK precursors (natural source of platelets) and UNIPV disruptive bioreactor made of a silk-scaffold to mimic the bone marrow conditions. These will be then complemented by IGR long-term experience in iPSC and MK biology, and ISENET cell quality control contribute to the standardization of the platelet production pipeline and its validation and verification. Under the guidance of our experienced tech transfer officers, by the end of the project we expect to complete the transition into a commercial innovation exploited by a next university spin-out.

Keywords: platelets,hematopoietic stem cells,ipsc,transfusions,bone marrow,bioreactor,biomaterials
For Tunable Thermochemical Energy Storage (4TunaTES)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Pathfinder
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: Netherlands,Germany,Italy,Belgium,Spain
Call: EIC Pathfinder Open (HORIZON-EIC-2023-PATHFINDEROPEN-01, 2023)
Start date: 2024-02-01
End date: 2028-01-31
Duration (months): 48.0
Total project cost (EUR): 2782213.76
EU funding (EUR): 2779713.75
Participants: 7
Project status: SIGNED

To accelerate the energy transition there is an urgent need for energy storage both for electricity and heat due to the intermittency of renewable resources. As a large part of our energy consumption is in form of thermal energy (78% in the built environment), and as there is a large amount of unused low temperature waste heat (8900 PJ in Europe), thermal energy storage offers route towards bridging availability and demand. Long term loss-free compact heat storage is the missing link, and Thermo-Chemical Energy Storage (TCES) has the potential to play this role. Unfortunately, present TCES concepts lack flexibility as a precise fit between the phase diagram of TCES-materials, the system design and the temperature demand of an application is needed. Therefore, most of the R&D for applying TCES is very specific for a particular application and switching to another application requires that much of the R&D process has to be redone. 4TunaTES will deliver a groundbreaking flexible TCES technology that can be easily adapted to different applications (variable in- and output temperatures) and thereby reduce the development costs by 90% as the R&D the process does not have be redone repeatedly. 4TunaTES develops a TCES-prototype that can be used for domestic use cases, which addresses three challenges: 1) radically new TCES materials with tunable phase diagrams by using a second gas or dopants, 2) heat exchanging components with a high degree of manufacturing flexibility, and 3) revolutionary systems with electricity adapted thermodynamic cycles. CNR and DLR will integrate the key findings in their high-TRL project portfolio, and Cellcius (CEL) will integrate the successful materials and designs in their technology. This will unlock the potential thermal energy storage. For this purpose, a strong consortium has been built which brings together computational material scientists (VUB), physical-chemists (TUE, CIIAE), mechanical engineers (CNR, DLR) and heat battery developer (CEL).

Keywords: thermochemical energy storage ultra low temperature heat tunable phase diagrams salt hydrates thermochemical materials flexible manufacturing chemical heat pump waste heat sorptive cooling
The Quantum Twisting Microscope - revolutionizing quantum matter imaging (QTM)

Framework: Horizon Europe — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Advanced grants
Action type: ERC actions
Panel: Condensed Matter Physics
Panel description: Structure, electronic properties, fluids, nanosciences, biological physics
Countries involved: Israel
Call: ERC ADVANCED GRANTS (ERC-2022-ADG, 2022)
Start date: 2023-04-01
End date: 2028-03-31
Duration (months): 60.0
Total project cost (EUR): 3344995.0
EU funding (EUR): 3344995.0
Participants: 1
Project status: SIGNED

In this work, we propose to build a radically new type of scanning probe microscope – the Quantum Twisting Microscope (QTM) – that will be the first capable of performing local quantum interference measurements at a twistable interface between two quantum materials. The concept, already established in preliminary experiments, is based on a unique tip made of an atomically-thin two-dimensional material. This tip allows electrons to coherently tunnel into a sample at many locations at once, making it a scanning electronic interferometer. With an extra twist degree of freedom, our microscope becomes a momentum-resolving local probe, providing powerful new ways to study the energy dispersions of interacting electrons in quantum materials. The same microscope, working in a second modality, will be the-first-of-its-kind platform for cryogenic assembly of interfaces between various van der Waals materials with full in-situ control over their twist angle. Finally, in a third modality, the QTM will make a dramatic jump, by two orders of magnitude, in the spatial resolution of electrostatic imaging. This will open a new world of interacting electron phenomena that were so far inaccessible to direct visualization. We have recently built a preliminary room temperature version of this microscope, and already observed striking quantum interference and promising results on all three fronts. By taking this new microscope to cryogenic temperatures, we expect to make multiple discoveries on a variety of fundamental questions in interacting quantum matter.

Keywords: graphene,magic angle twisted bilayer graphene,scanning probe microscopes
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours (ScanNanoTreat)

Framework: Horizon Europe — Innovative Europe
Programme: The European Innovation Council (EIC)
Theme: EIC Transition
Destination: Open to supporting projects in all areas of science, technology,...
Action type: EIC actions
Countries involved: France,Netherlands,Ireland
Call: Transition Open 2024 (HORIZON-EIC-2024-TRANSITION-01, 2024)
Start date: 2025-06-01
End date: 2028-05-31
Duration (months): 36.0
Total project cost (EUR): 2815500.54
EU funding (EUR): 2499911.25
Participants: 6
Project status: SIGNED

Cancer treatment is a significant healthcare challenge, costing Europe up to €199 billion annually. The burden will grow substantially, with a projected 60% increase in cancer cases from 2018 to 2040. To address these challenges, the ScanNanoTreat consortium consisting of Claude Bernard Lyon 1 University, Maastricht University, Guerbet, Philips, and Inlecom Commercial Pathways is developing a revolutionary theranostic approach combining advanced photonics and nanotechnology. The innovative system integrates Spectral Photon Counting Computed Tomography (SPCCT) with X-ray-activated Photodynamic Therapy (X-PDT) using gadolinium-based nanoprobes. This approach enables simultaneous imaging and treatment of solid tumours, with an initial focus on breast and pancreatic cancers. By leveraging low-energy X-rays and optimized nanoprobes, ScanNanoTreat aims to reduce radiation doses by over 30% compared to conventional radiotherapy. This technology is expected to radically shorten the diagnosis-treatment cycle, leading to improved prognosis and better patient outcomes, and up to 40% reduction in cancer treatment costs. If successfully deployed, ScanNanoTreat could revolutionize the European theranostic market, aiming to capture 10-17% of the projected €493 million market by 2032, suggesting a potential market size of €35-€60 million by 2035. The project will advance the technology from TRL 3 to TRL 5, preparing for clinical trials by 2027 and potential market entry by 2035. Additionally, a business plan and exploitation strategy will be developed, targeting a spinoff creation to commercialize the technology. The support of the EIC Transition grant is crucial to conduct preclinical studies, optimize the SPCCT system, and develop a comprehensive regulatory strategy. By addressing critical healthcare needs and aligning with EU strategic autonomy in MedTech, ScanNanoTreat will radically improve cancer care and contribute to the sustainability of European healthcare systems.

Keywords: theranostic nanoprobes,x ray activated photodynamic therapy,spectral photon counting ct,solid tumor treatment,gadolinium based nanoparticles,low dose radiation therapy,precision o
Sustainable Hydrogen Storage by Advanced Layered Magnesium-based Nanostructured Alloys (SHSBALMBNA)

Framework: Horizon Europe — Excellent Science
Programme: Marie Skłodowska-Curie Actions (MSCA)
Theme: Marie Skłodowska-Curie
Destination: Postdoctoral Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Information Science and Engineering
Countries involved: Germany,United States
Call: MSCA Postdoctoral Fellowships 2023 (HORIZON-MSCA-2023-PF-01, 2023)
Start date: 2024-07-01
End date: 2026-06-30
Duration (months): 24.0
Total project cost (EUR): 189687.36
EU funding (EUR): 189687.36
Participants: 2
Project status: SIGNED

The generation of advanced alloys with extraordinary sustainable, functional performance is a game changer for commercializing advanced manufacturing technologies and is a key issue for the 4th industrial revolution, considering the environmental issues to reduce CO2 emission, as well. To this end, thermally stable, high-performance bulk nanostructured (nano-layered) nanocomposites containing stable interfaces are highly desirable for hydrogen storage. Within the proposed project, the newly developed accumulative fold-forging (AFF) method shall be applied to enhance the hydrogen storage response of a Mg/Nb alloy based on extreme grain refinement down to the nano-scale and the synthesis of a nano-layered structure. This novel alloy design will assess this synergy between advanced manufacturing by a novel severe plastic deformation (SPD) approach and metal physics as an interdisciplinary topic. First, the advanced layered system will be designed by AFF for nano-grains formation and forced alloying between Mg and Nb. Then, the manufactured new materials shall be characterized in terms of structural features, mechanical properties, and functional behaviour. Third, atomic-scale structural modelling will proceed to simulate sustainable hydrogen storage performance. These experiments may give novel insights into tailoring the pathways toward sustainable microstructural design for optimizing the composition and structure of advanced Mg/Nb nanostructured alloys with extraordinary storage capacity and cyclic stability. Coming from the world-foremost centers on advanced manufacturing and alloy design, I will bring new scientific and technological knowledge to the host university and institute. Meanwhile, practical training at one of Germany’s best universities and research institutes, progressing the current state-of-the-art by developing metal physics of advanced nanostructured alloys and high-quality publications, can prepare me for a professorship position in the EU or NA.

Keywords: severe plastic deformation spd accumulative fold forging aff magnesium foil layered nanostructured materials microstructure physics functional property sustainable hydrogen storage behaviour
European Open Compute Architecture for Powerful Edge (CAPE)

Framework: Horizon Europe — Global Challenges and European Industrial Competitiveness
Programme: Digital, Industry and Space
Theme: Digital
Destination: Digital & Emerging Technologies for Competitiveness and Fit for the Green Deal
Action type: Research and Innovation actions
Countries involved: Hungary,Germany,France,Greece,Switzerland,United States,Netherlands
Call: Open Source for Cloud/Edge to support European Digital Autonomy (RIA) (HORIZON-CL4-2024-DIGITAL-EMERGING-01-CNECT, 2024)
Start date: 2024-12-01
End date: 2027-11-30
Duration (months): 36.0
Total project cost (EUR): 5996250.0
EU funding (EUR): 5996250.0
Participants: 12
Project status: SIGNED

CAPE (European Open Compute Architecture for Powerful Edge) aims to redefine the landscape of edge-cloud computing infrastructures by developing the EdgeMicroDataCenters (EMDC's) and eHPS as a 'new unit of computing' for data-dense edge environments. The project designs and showcase an innovative, open hardware platform that is dynamically composable via CXL to answer the end user needs. EMDC and eHPS provides an open high density platform for heterogeneous computing units (XPU), RISC-V architectures all based on industry-standard form factor, COM-HPC that is supported by a robust ecosystem of Original Equipment Manufacturers (OEMs) within Europe, ensuring wide accessibility and adoption. To allow end users to be digital sovereign e.g. manage the governance of data, AI models, applications deployed across an ‘edge-first’ edge to cloud continuum, CAPE will employ a cloud-agnostic overlay known as Infrastructure from Code (IfC). This innovative approach abstracts the complexities inherent in diverse cloud computing infrastructures and services, empowering software developers to deploy applications effortlessly across the edge-to-cloud continuum. This is achieved without necessitating extensive knowledge of the underlying cloud infrastructure, enabling deployments across on-premise and off-premise, public and private cloud environments with minimal complexity. CAPE's solution will be validated in 3 use cases: the management of intelligent electric energy microgrids, edge AI and satellite communications. All usecases will evaluate RISC-V (EPI) and CXL solutions. Each usecase will be evaluated on technical, economical and sustainability aspects and benchmarked against legacy hardware in local clouds against edge-optimized data centers.

Keywords: digital sovereignty energy efficiency cognitive edge cloud computing hardware acceleration federated resource management risc v cxl infrastructure from code sustainability heterogeneity